PubRank

Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Clinical Trial ID NCT01685125

PubWeight™ 12.29‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01685125

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. Oncogene 2014 1.31
2 Molecular pathways and targets in prostate cancer. Oncotarget 2014 1.00
3 Targeting the adaptive molecular landscape of castration-resistant prostate cancer. EMBO Mol Med 2015 0.93
4 Growth factor and signaling pathways and their relevance to prostate cancer therapeutics. Cancer Metastasis Rev 2014 0.92
5 Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions. Curr Oncol 2012 0.89
6 Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer. Cell 2016 0.89
7 Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int J Mol Sci 2013 0.88
8 Cell mates: paracrine and stromal targets for prostate cancer therapy. Nat Rev Urol 2013 0.87
9 Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer. Clin Med Insights Urol 2013 0.85
10 CYP17A1 inhibitors in castration-resistant prostate cancer. Steroids 2015 0.84
11 Emerging molecularly targeted therapies in castration refractory prostate cancer. Prostate Cancer 2013 0.83
12 Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer. Clin Med Insights Oncol 2016 0.83
13 Androgen pathway resistance in prostate cancer and therapeutic implications. Expert Opin Pharmacother 2015 0.77
14 Drugs that offer a survival advantage for men with bone metastases resulting from castration-resistant prostate cancer: new and emerging treatment options. P T 2014 0.75
Next 100